Difficult-to-Control Diabetes: Is Cortisol at Play?

January 8, 2024

• 2023 • Roundtable Discussion

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

June 20, 2023

Simeoli et al. • 2023 • ENDO 2023

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

June 9, 2023

Frias et al. • 2023 • 7th annual Heart in Diabetes CME Conference

An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

June 4, 2023

Badiu et al. • 2023 • European Congress of Endocrinology

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

June 1, 2023

Frias et al. • 2023 • AACE 2023